As neurologic findings among patients with COVID-19 emerge, comparison to sequelae seen with other coronaviruses is instructive.
Donanemab Label Revised: New Dosing Schedule Approved for Early Alzheimer’s Treatment
The FDA approved updated dosing for donanemab in early Alzheimer disease, reducing ARIA-E risk by 41% without compromising efficacy.
The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment
Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.
Clinic- and System-Level Factors Drive Racial Disparities in COVID-19 Antiviral Prescribing, Study Finds
A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Mayo Clinic AI Tool Allows Rapid, Precise Identification of 9 Types of Dementia From Single Brain Scan
The StateViewer clinical decision support system could help expand access to specialist-level insights in clinics that lack neurology expertise, according to researchers.
Adjuvanted Vaccine Against RSV Associated with Substantial Reduced Risk of Dementia
The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.